10.3389/fphys.2018.01622 Summary Keywords dipeptidyl peptidase-4, glucagon-like peptide-1, incretin, peptide degradation, therapy, type 2 diabetes Citation Deacon CF (2019) Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
However, the association between SGLT2-i and systemic RAAS activation is not straightforward
FDA Warning: RISK FOR ILEUS (INTESTINAL BLOCKAGE) (FDA 09/22/2023) Amongst more than 8,500 voluntary reports of GI disorders associated with the use of semaglutide reported through June 30, 2023, ileus was included in 33 cases, and two cases of death
In this issue of Diabetologia , Hogan and colleagues report an improvement of psoriasis in three obese patients with type 2 diabetes several weeks after the initiation of therapy with the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) agonists exenatide and liraglutide [2]
Build Exercise Habits and Daily Routines Incorporating exercise into your routine can improve GLP-1 outcomes while keeping your motivation steady
Khafagy R, Dash S